CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Descriptor ID |
D018414
|
MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 0 | 2 | 2 |
1997 | 1 | 1 | 2 |
1998 | 1 | 1 | 2 |
1999 | 1 | 1 | 2 |
2000 | 1 | 2 | 3 |
2001 | 3 | 2 | 5 |
2002 | 1 | 2 | 3 |
2003 | 0 | 4 | 4 |
2004 | 5 | 2 | 7 |
2005 | 3 | 2 | 5 |
2006 | 6 | 3 | 9 |
2007 | 5 | 4 | 9 |
2008 | 5 | 7 | 12 |
2009 | 11 | 4 | 15 |
2010 | 3 | 7 | 10 |
2011 | 2 | 3 | 5 |
2012 | 3 | 6 | 9 |
2013 | 7 | 4 | 11 |
2014 | 8 | 5 | 13 |
2015 | 4 | 5 | 9 |
2016 | 3 | 4 | 7 |
2017 | 6 | 3 | 9 |
2018 | 5 | 4 | 9 |
2019 | 11 | 9 | 20 |
2020 | 6 | 11 | 17 |
2021 | 12 | 12 | 24 |
2022 | 5 | 15 | 20 |
2023 | 2 | 7 | 9 |
2024 | 11 | 10 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Virus Protein-Specific Immune Responses in Selective Depletion of Lymphocyte Populations Using Monoclonal Antibodies in Bolivian Squirrel Monkeys (Saimiri boliviensis boliviensisv). Viral Immunol. 2025 Jan-Feb; 38(1):12-22.
-
Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance. J Endocrinol Invest. 2025 Mar; 48(3):765-775.
-
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro Oncol. 2024 Dec 05; 26(12):2239-2255.
-
Anti-CD8/IL-15 (N72D)/sushi fusion protein: A promising strategy for improvement of cancer immunotherapy. Cytokine. 2025 Jan; 185:156822.
-
Tumor Expression of CD83 Reduces Glioma Progression and Is Associated with Reduced Immunosuppression. Cancer Res Commun. 2024 12 01; 4(12):3209-3223.
-
Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
-
CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: A Review. JCO Precis Oncol. 2024 Oct; 8:e2400183.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 Nov 26; 121(48):e2322356121.
-
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. Gut. 2024 Nov 11; 73(12):1984-1998.
-
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024 Nov 13; 32(11):2004-2018.e9.